Equillium announces publication of abstract for the annual congress of the european hematology association

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the european hematology association (eha) has published an abstract highlighting the phase 3 equator study in first-line acute graft-versus-host disease (agvhd). title: equator: a pivotal phase 3 double-blind, randomized, placebo-controlled study of
EQ Ratings Summary
EQ Quant Ranking